BCG downregulates PD1 and PD-L1 expression in bladder cancer cells co-cultivated with peripheral blood mononuclear cells

BCG downregulates PD1 and PD-L1 expression in bladder cancer cells co-cultivated with peripheral blood mononuclear cells

Abstract Purpose BCG is the standard of care to treat high risk non-muscle invasive bladder cancer (NMIBC), reducing recurrence. PD-L1 is a ligand of the co-inhibitory receptor PD1 that has been shown to be expressed by tumor cells of distinct origin related to unfavorable prognosis. The development...

Full description

Bibliographic Details
Main Authors: Katia R. M. Leite, Denis Reis Morais, Cristina Massoco, Sabrina T. Reis, Nayara I. Viana, Iran A. Silva, Vanessa Guimaraes, Ruan Pimenta, Gabriel Arantes, Miguel Srougi, Willian Carlos Nahas
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Surgical and Experimental Pathology
Subjects:
Bladder cancer
BCG
PD1
PD-L1
Cell culture
qRT-PCR
Online Access:https://doi.org/10.1186/s42047-022-00123-9

Internet

https://doi.org/10.1186/s42047-022-00123-9

Similar Items